News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Daniel Heng: Treatment free survival is becoming an important endpoint in different mRCC treatments
Daniel Heng/X
Feb 3, 2025, 14:07

Daniel Heng: Treatment free survival is becoming an important endpoint in different mRCC treatments

Daniel Heng, Head of Medical Oncology at the Arthur J.E. Child Comprehensive Cancer Centre in Calgary, Alberta, posted on X about recent paper by Mehul Gupta et al., titled “Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis” published on European Urology Oncology.

Authors: Mehul Gupta, Connor Wells, Meredith M. Regan, Wanling Xie, Vishal Navani, Renee Maria Saliby, Naveen S. Basappa, Frede Donskov, Takeshi Yuasa, Kosuke Takemura, Christian K. Kollmannsberger, Megan Crumbaker, Aly-Khan A. Lalani, Thomas Powles, Hedyeh Ebrahimi, Rana R. McKay, Jae-Lyun Lee, Ravindran Kanesvaran, Toni K. Choueiri, Daniel Y.C. Heng

Daniel Heng: Treatment free survival is becoming an important endpoint in different mRCC treatments

“Treatment free survival is becoming an important endpoint when looking at different mRCC treatments. VEGF alone had shortest TFS. Something to be said about treatment breaks.”

cancer Connor Wells Daniel Heng Daniel Y.C. Heng Mehul Gupta Meredith M Regan Naveen S. Basappa OncoDaily Oncology Ravindran Kanesvaran Renee Maria Saliby Toni K. Choueiri Vishal Navani Wanling Xie
Special Coverage
Voices
Aug 21, 2025, 23:33
Ohio State Launches Groundbreaking First-in-Human Cancer Drug Trial
Societies
Aug 21, 2025, 23:08
Empowering Cancer Survivors Through the Believe In You Program - Sylvester Comprehensive Cancer Center
Insight
Aug 21, 2025, 20:26
Kevin Harrington Looks Forward to CONCORDE Study Results on DNA Damage Inhibitors and Radiotherapy
Voices
Aug 21, 2025, 20:00
Raymond Mailhot: Advancing Hodgkin Lymphoma Survivor Study with NCI Funding
Voices
Aug 21, 2025, 19:28
Parvati Tiwari: Advocates Express Alarm Over NCI’s Decision to End PBTC Funding for Pediatric Brain Tumor Trials
Voices
Aug 21, 2025, 15:59
George Kumar: The interplay Between Cardiovascular Disease (CVD) and Cancer
Voices
Aug 21, 2025, 15:47
European Society of Gynaecological Oncology Announces that Applications are Open for Editor-in-Chief of IJGC
Insight
Aug 21, 2025, 15:37
Carolina Reduzzi: ctDNA Landscape Analysis Post CDK4/6 Inhibitor in HR+/HER2- Metastatic Breast Cancer
Voices
Aug 21, 2025, 15:30
Clinician-Scientists Awarded NMRC Transition Awards for Precision Lung Cancer Research - National Cancer Centre Singapore
Voices
Aug 21, 2025, 15:22
Construction of the $658 million Sydney Children’s Hospital Stage One and MCCCC Project Has Reached Completion
Oncolibrary
Aug 21, 2025, 15:00
Breakthrough Emactuzumab Phase 3 TANGENT Trial in TGCT: SynOx Pharma Reports Enrollment Completed Ahead of Schedule
Voices
Aug 21, 2025, 14:50
Andrea Apolo Highlights the Top 5 Clinical Advances in Bladder Cancer Treatment for 2024